Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Sylvain Garciaz, Yves Collette, Remy Castellano, Michel Aurrand-Lions, Helene Sicard, Laetitia Jentreau, Norbert Vey, Cecile Bougeret

Blood (2022) 140 (Supplement 1): 7800–7801.

https://doi.org/10.1182/blood-2022-166820

Published: 2022

Journal Articles

KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target

Blood (2022) 140 (13): 1522–1532.

https://doi.org/10.1182/blood.2022016765

Published: 2022

Includes: Supplemental data

Journal Articles

IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial

Martine Bagot, MD PhD, Pierluigi Porcu, MD, Basem M. William, MRCP,MD, Maxime Battistella, MD PhD, Maarten Vermeer, MD PhD, Sean Whittaker, MD FRCP, Caroline Ram-Wolff, MD, Michael S Khodadoust, MDPhD, Helene Sicard, PhD, Hatem A Azim, Jr., MD PhD, Youn H. Kim, MD

Blood (2018) 132 (Supplement 1): 684.

https://doi.org/10.1182/blood-2018-99-118021

Published: 2018

Journal Articles

KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting

Maxime Battistella, Christophe Leboeuf, Caroline Ram-Wolff, Charlotte Hurabielle, Cécile Bonnafous, Hélène Sicard, Armand Bensussan, Martine Bagot, Anne Janin

Blood (2017) 130 (26): 2900–2902.

https://doi.org/10.1182/blood-2017-06-792382

Published: 2017

Includes: Supplemental data

Journal Articles

First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results

Blood (2016) 128 (22): 1826.

https://doi.org/10.1182/blood.V128.22.1826.1826

Published: 2016

Journal Articles

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Guy Laurent, MD, PhD, Sylvie Lafaye de Micheaux, MD, Philippe Solal-Celigny, MD, Pierre Soubeyran, MD, PhD, Vincent Delwail, Hervé Ghesquières, MD, Catherine Thieblemont, MD, Eric Jourdan, MD, PhD, Lucile Beautier, Fabien Audibert, Patrick Squiban, MD, Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD

Blood (2009) 114 (22): 1649.

https://doi.org/10.1182/blood.V114.22.1649.1649

Published: 2009

Journal Articles

TCR and DNAM Dependent Lysis of Acute Monocytic Leukemia (AMoL) by Vg9Vd2 T Lymphocytes.

Julie Gertner-Dardenne, Eloise Perrot, Thomas Prebet, MD, Aude Charbonnier, Helene Sicard, PhD, Norbert Vey, Daniel Olive, MD, PhD

Blood (2009) 114 (22): 1041.

https://doi.org/10.1182/blood.V114.22.1041.1041

Published: 2009

Journal Articles

IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study.

Claire Lucas, Sophie Ingoure, Elodie Soule, Bruna Faria, Fabien Audibert, Mathieu Blery, Lucile Beautier, Francois Romagne, PhD, Sylvie de Micheaux, MD, Helene Sicard, PhD

Blood (2009) 114 (22): 583.

https://doi.org/10.1182/blood.V114.22.583.583

Published: 2009

Journal Articles

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

Julie Gertner-Dardenne, Cecile Bonnafous, Christine Bezombes, Aude-Hélène Capietto, Virginie Scaglione, Sophie Ingoure, Delphine Cendron, Emilie Gross, Jean-François Lepage, Anne Quillet-Mary, Loîc Ysebaert, Guy Laurent, Hélène Sicard, Jean-Jacques Fournié

Blood (2009) 113 (20): 4875–4884.

https://doi.org/10.1182/blood-2008-08-172296

Published: 2009

Includes: Supplemental data

Journal Articles

Phosphoantigen-activated Vγ2Vδ2 T cells antagonize IL-2–induced CD4 + CD25 + Foxp3 + T regulatory cells in mycobacterial infection

Guangming Gong, Lingyun Shao, Yunqi Wang, Crystal Y. Chen, Dan Huang, Shuyu Yao, Ximei Zhan, Helene Sicard, Richard Wang, Zheng W. Chen

Blood (2009) 113 (4): 837–845.

https://doi.org/10.1182/blood-2008-06-162792

Published: 2009

Includes: Supplemental data

Journal Articles

In Follicular Lymphoma (FL), γδt-Lymphocytes (γδT) Are Present and Expandable from Peripheral Blood and Rare in Tumour Lymph Nodes, Mostly in Peri-Follicular Areas.

Mounia Braza, Therese Rousset, Majda Saifi, Guillaume Cartron, Sylvie Lafaye de Micheaux, Helene Sicard, Patrick Squiban, Valérie Costes, Jean-Francois Rossi

Blood (2008) 112 (11): 1773.

https://doi.org/10.1182/blood.V112.11.1773.1773

Published: 2008

Journal Articles

Cognitive Study of Reactivity to IPH1101 of Peripheral γδ T Lymphocytes from Chronic Myeloid Leukemia, Multiple Myeloma and Follicular Lymphoma Patients.

Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD, Philippe Rousselot, MD, Alexis Collette, Christine Paiva, Sophie Ingoure, Sylvie Lafaye de Micheaux, MD

Blood (2008) 112 (11): 1530.

https://doi.org/10.1182/blood.V112.11.1530.1530

Published: 2008

Journal Articles

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Guy Laurent, MD, PhD, Jean François Rossi, MD, PhD, Eric W Van Den Neste, MD, PhD, Fabien Audibert, Hervé Ghesquières, MD, Steven Le Gouill, MD, PhD, Pierre Feugier, MD, Helene Sicard, PhD, Sophie Ingoure, Elodie Soule, Sylvie Lafaye de Micheaux, MD

Blood (2008) 112 (11): 1002.

https://doi.org/10.1182/blood.V112.11.1002.1002

Published: 2008

Journal Articles

Enhancing Lysis of B Cell Lymphoma by Innovative γδ T Cell Immunotherapies Using Agonist IPH1101 (Phosphostim, BrHPP).

Jean-Francois Rossi, PhD, MD, Julie Gertner, Helene Sicard, PhD, Guy Laurent PhD, MD, Sylvie Lafaye de Micheaux, MD, Jerome Tiollier, PhD, Jean-Jacques Fournie, PhD, Patrick Squiban, MD, Volker Kunzmann PhD, MD

Blood (2006) 108 (11): 5201.

https://doi.org/10.1182/blood.V108.11.5201.5201

Published: 2006

NARROW

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target

IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial

KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting

First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

TCR and DNAM Dependent Lysis of Acute Monocytic Leukemia (AMoL) by Vg9Vd2 T Lymphocytes.

IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study.

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

Phosphoantigen-activated Vγ2Vδ2 T cells antagonize IL-2–induced CD4 + CD25 + Foxp3 + T regulatory cells in mycobacterial infection

In Follicular Lymphoma (FL), γδt-Lymphocytes (γδT) Are Present and Expandable from Peripheral Blood and Rare in Tumour Lymph Nodes, Mostly in Peri-Follicular Areas.

Cognitive Study of Reactivity to IPH1101 of Peripheral γδ T Lymphocytes from Chronic Myeloid Leukemia, Multiple Myeloma and Follicular Lymphoma Patients.

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Enhancing Lysis of B Cell Lymphoma by Innovative γδ T Cell Immunotherapies Using Agonist IPH1101 (Phosphostim, BrHPP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only